LPAAT-β inhibitors and uses thereof
AssigneeCell Therapeutics, Inc.
InventorsLynn Bonham, Baoqing Gong, Robert E Finney, David M Hollenback, J Peter Klein, David W Leung, Scott A Shaffer, Norina M Tang, John Tulinsky, Thayer H White
Life of this patent
Estimating the term…
Abstract
The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase β (LPAAT-β) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-β activity.
Claims8
A compound selected from N-benzo[1,3]dioxol-5-yl -6-chloro-N′-(4-chlorophenyl)-[1,3,5]triazine-2,4-diamine, 6-chloro-N-(2,3-dihydrobenzo [1,4]dioxin-6-yl)-N′-phenyl-[1,3,5]triazine-2,4-diamine, N-benzo[1,3]dioxol-5-yl-6-chloro-N′-phenyl-[1,3,5]triazine-2,4-diamine, 6-chloro-N-indan-5-yl-N′-phenyl-[1,3,5]triazine-2,4-diamine, 6-chloro-N-(4-chlorophenyl)-N′-(4-methoxyphenyl)-[1,3,5]triazine-2,4-diamine and 6-chloro-N-(4-chlorophenyl)-N′-phenyl-[1,3,5]-triazine-2,4-diamine, or pharmaceutically acceptable salts thereof.
Dependencies are inferred from the claim text.